Journal article
The landscape of new drugs in lymphoma
A Younes, S Ansell, N Fowler, W Wilson, S De Vos, J Seymour, R Advani, A Forero, F Morschhauser, MJ Kersten, K Tobinai, PL Zinzani, E Zucca, J Abramson, J Vose
Nature Reviews Clinical Oncology | NATURE PORTFOLIO | Published : 2017
Abstract
The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel com..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
A.Y. receives honouraria and/or consults for Abbvie, Bayer, BMS, Celgene, Gilead, Incyte, Janssen R&D, Sanofi, Seattle Genetics, Merck,, and Takeda Millenium, and research support from the John and Barbara Vogelstein Foundation. The other authors declare no competing interests.